

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K/A**  
(Amendment No. 1)

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**September 18, 2019**  
Date of Report (Date of earliest event reported)

---

**X4 Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-38295**  
(Commission  
File Number)

**27-3181608**  
(IRS Employer  
Identification No.)

**955 Massachusetts Avenue, 4th Floor**  
**Cambridge, Massachusetts**  
(Address of principal executive offices)

**02139**  
(Zip Code)

**Registrant's telephone number, including area code: (857) 529-8300**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	XFOR	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

### Explanatory Note

In accordance with Instruction No. 2 to Item 5.02 of Form 8-K, X4 Pharmaceuticals, Inc. (the “Company”) is filing this Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment Filing”) to amend the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on September 20, 2019 (the “Original Filing”). Except as expressly set forth herein, this Amendment Filing does not amend, modify or update the disclosures contained in the Original Filing.

#### **Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

As reported in the Original Filing, on September 18, 2019, the Board of Directors (the “Board”) of the Company appointed William E. Aliski to the Board as a Class II director. Committee assignments for Mr. Aliski were not determined as of filing of the Original Filing.

On October 17, 2019, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Mr. Aliski to its Compensation Committee, effective immediately. Following the appointment, the membership of the Compensation Committee consists of: Murray Stewart (chair), Gary J. Bridger and Mr. Aliski.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 18, 2019

**X4 PHARMACEUTICALS, INC.**

By: /s/ Adam S. Mostafa  
Adam S. Mostafa  
Chief Financial Officer